| New Day Rising Llc | |
|
21545 170th St Birmingham IA 52535-8044 | |
| (641) 919-9388 | |
| Not Available |
| Full Name | New Day Rising Llc |
|---|---|
| Speciality | Counselor - Mental Health |
| Location | 21545 170th St, Birmingham, Iowa |
| Authorized Official Name and Position | Sara Jones (OWNER) |
| Authorized Official Contact | 6419199388 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| New Day Rising Llc 21545 170th St Birmingham IA 52535-8044 Ph: (641) 919-9388 | New Day Rising Llc 21545 170th St Birmingham IA 52535-8044 Ph: (641) 919-9388 |
| NPI Number | 1629821152 |
|---|---|
| Provider Enumeration Date | 04/05/2024 |
| Last Update Date | 04/08/2024 |
| Certification Date | 04/08/2024 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629821152 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
News Archive
Scientists at the national scientific research center at the University of Paris in France, discovered the link between trans-fats and breast cancer after carrying out a study of women taking part in a large European cancer trial.
Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.
Giving clot-busting drugs to patients who wake up with stroke symptoms appears to be as safe as giving it to those in the recommended three-hour window, according to researchers at The University of Texas Medical School at Houston.
Emerging Healthcare Solutions, Inc. disclosed today that Stand-By Systems has favorably completed their US Government Central Contractor Registration and is now eligible to sell their breakthrough products to the federal government. EHSI has verified the federal eligibility as part of their due diligence related to an option with Stand-By Systems (SBS), owner of the FDA approved SBS 1615 catalytic oxygen generator and associated systems. The option agreement allows EHSI management to perform due diligence prior to finalizing a definitive agreement.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept's product candidate AZD1446 as a treatment for Alzheimer's disease.
› Verified 6 days ago